BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

Menten AI

Menten AI logo

Website
https://menten.ai/
Founded
2018
Publications
4

Technologies

AI Companies (Drug Discovery) Quantum Theory in Drug Discovery

Menten is a biotech startup developing a software platform for protein design empowered by machine learning and quantum computing. Menten’s quantum approach aims to overcome the scalability challenges that limit classical methods in computational protein design to significantly improve accuracy and reduce development time. Menten’s goal is to create the computational tools required to deliver on the promise of protein-based medicine and biocatalysis.

quantum computing protein design

Interviews

[Interview] This Company Brings Quantum Tech Into Protein Design

Posts Mentioning This Company

14 Companies Using Quantum Theory For Drug Discovery (Including 2 Going Public)

14 Companies Using Quantum Theory To Accelerate Drug Discovery (Including 2 Going Public)

Feb. 24, 2024  
(Updated: 24.02.2024) Molecular mechanics (MM) is a traditional computational approach when it comes to modeling in synthetic organic chemistry, medicinal chemistry, and versatile aspects of drug design. However, MM methods have significant limitations, for example, when used to study electron-based properties within the drug-receptor microenvironment. Quantum mechanical (QM) methods allow …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

By taking a hybrid quantum-classical computing approach using D-Wave’s 2000Q quantum system, Menten hopes to be able to significantly reduce the cost and time required to engineer proteins for drug design, as well as overcome the scalability challenges that limit classical approaches. The hybrid approach has already resulted in better solutions, faster

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.